Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9799039 | 1.00 | CA2 (0.50) | CA2TSHRSMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL31424266 | 1.00 | CA2 (0.50) | CA2TSHRSMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL12883057 | 0.98 | CA2 (0.49) | CA2TSHRSMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL22710100 | 0.98 | CA2 (0.49) | CA2TSHRSMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL13248148 | 0.98 | CA2 (0.49) | CA2TSHRSMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL9972151 | 0.98 | CA2 (0.49) | CA2TSHRSMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL9798873 | 0.92 | CA2 (0.46) | CA2TSHRSMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL9798886 | 0.92 | CA2 (0.46) | CA2TSHRSMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL10452650 | 0.92 | CA2 (0.46) | CA2TSHRSMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL7875753 | 0.85 | CA2 (0.59) | CA2TSHRSMN1; SMN2ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2104716-B1 | TINTED CLEAR COATINGS UV STABILIZED WITH 2-HYDROXY PHENYL TRIAZINE | BASF SE (DE) | 2018-02-21 | — | — | EP | disclosed |
| US-20150079412-A1 | TINTED CLEAR COATINGS UV STABILIZED WITH 2-HYDROXY PHENYL TRIAZINE | BASF SE (DE) | 2015-03-19 | — | — | US | disclosed |
| US-8895068-B2 | Nanoparticle composition and associated methods thereof | GENERAL ELECTRIC COMPANY (US) | 2014-11-25 | — | — | US | disclosed |
| US-8889103-B2 | Diagnostic agent composition and associated methods thereof | GENERAL ELECTRIC COMPANY (US) | 2014-11-18 | — | — | US | disclosed |
| US-8262945-B2 | Stabilization of photochromic systems | BASF SE (DE) | 2012-09-11 | — | — | US | disclosed |
| US-20120156141-A1 | NANOPARTICLE COMPOSITION AND ASSOCIATED METHODS THEREOF | GENERAL ELECTRIC COMPANY (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120156142-A1 | DIAGNOSTIC AGENT COMPOSITION AND ASSOCIATED METHODS THEREOF | GENERAL ELECTRIC COMPANY (US) | 2012-06-21 | — | — | US | disclosed |
| US-7771709-B2 | Polyethersiloxane copolymer | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2010-08-10 | — | — | US | disclosed |
| US-20100119858-A1 | TINTED CLEAR COATINGS FOR WOOD | CIBA CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100062270-A1 | TINTED CLEAR COATINGS UV STABILIZED WITH 2-HYDROXY PHENYL TRIAZINE | CIBA CORPORATION (US) | 2010-03-11 | — | — | US | disclosed |
| US-20090289236-A1 | STABILIZATION OF PHOTOCHROMIC SYSTEMS | DESTRO MARA | 2009-11-26 | — | — | US | disclosed |
| US-7288583-B2 | Method of content protection with durable UV absorbers | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2007-10-30 | — | — | US | disclosed |
| US-7214742-B2 | 2-hydroxyphenyl-s-triazine crosslinkers for polymer networks | CIBA SPECIALTY CHEMICALS CORP. (US) | 2007-05-08 | — | — | US | disclosed |
| US-20070064195-A1 | Stabilization of photochromic systems | CIBA CORPORATION | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120156142-A1 | DIAGNOSTIC AGENT COMPOSITION AND ASSOCIATED METHODS THEREOF | PHOSPHO1, PHAX, PIK3CA | CA2 1362/4885TSHR 2562/4885SMN1; SMN2 1720/4885 |
| US-20120156141-A1 | NANOPARTICLE COMPOSITION AND ASSOCIATED METHODS THEREOF | PHOSPHO1, PIK3CA, PTEN | CA2 2456/4885TSHR 3625/4885SMN1; SMN2 3395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.